{"hands_on_practices": [{"introduction": "The foundation of cost-effectiveness analysis is the Incremental Cost-Effectiveness Ratio (ICER), which quantifies the additional cost per unit of health benefit gained. This first exercise walks you through a fundamental calculation involving two competing health strategies. The scenario presented leads to a negative ICER, which represents a special case known as \"dominance\"â€”where a new intervention is both more effective and less costly, making it the unequivocally superior choice. Mastering the interpretation of this scenario is a crucial first step in applying CEA principles [@problem_id:4582264].", "problem": "An influenza prevention program is implemented in a metropolitan cohort. Two strategies are compared over a $10$-year horizon with costs expressed in United States dollars (USD) and health benefit measured as Quality-Adjusted Life Years (QALYs). Strategy $\\mathcal{N}$ is an enhanced vaccination program integrated into primary care, and strategy $\\mathcal{C}$ is the current standard of care without enhancements. The present-value cost and effectiveness for an average adult are estimated from a validated cohort model as follows: strategy $\\mathcal{N}$ has total cost $C_{\\mathcal{N}} = \\$4{,}350$ and total effectiveness $E_{\\mathcal{N}} = 7.982$ QALYs; strategy $\\mathcal{C}$ has total cost $C_{\\mathcal{C}} = \\$5{,}550$ and total effectiveness $E_{\\mathcal{C}} = 7.778$ QALYs. Using fundamental epidemiological cost-effectiveness definitions, compute the Incremental Cost-Effectiveness Ratio (ICER) for strategy $\\mathcal{N}$ compared to strategy $\\mathcal{C}$. Then, classify the result in terms of the signs of the incremental effectiveness $\\Delta E$ and incremental cost $\\Delta C$, and interpret what a negative ICER implies within the cost-effectiveness plane quadrant framework. Report the ICER value. Round your answer to four significant figures and express the final ICER in United States dollars per Quality-Adjusted Life Year (USD per QALY).", "solution": "The problem statement is assessed to be valid. It is scientifically grounded in the principles of epidemiological cost-effectiveness analysis, objective, and well-posed. All the necessary data for the calculation are provided, and there are no internal contradictions or ambiguities.\n\nThe primary task is to compute the Incremental Cost-Effectiveness Ratio (ICER) for a new intervention (strategy $\\mathcal{N}$) compared to the current standard of care (strategy $\\mathcal{C}$). The ICER is a fundamental metric in health economics used to evaluate the value for money of a health intervention. It is defined as the ratio of the change in costs to the change in health benefits (effectiveness) of the new strategy relative to the comparator.\n\nThe formula for the ICER is:\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta E} = \\frac{C_{\\mathcal{N}} - C_{\\mathcal{C}}}{E_{\\mathcal{N}} - E_{\\mathcal{C}}}\n$$\nwhere:\n- $\\Delta C$ is the incremental cost.\n- $\\Delta E$ is the incremental effectiveness.\n- $C_{\\mathcal{N}}$ and $E_{\\mathcal{N}}$ are the cost and effectiveness of the new strategy ($\\mathcal{N}$).\n- $C_{\\mathcal{C}}$ and $E_{\\mathcal{C}}$ are the cost and effectiveness of the comparator strategy ($\\mathcal{C}$).\n\nFrom the problem statement, the given values are:\n- Cost of strategy $\\mathcal{N}$: $C_{\\mathcal{N}} = \\$4{,}350$\n- Effectiveness of strategy $\\mathcal{N}$: $E_{\\mathcal{N}} = 7.982$ QALYs\n- Cost of strategy $\\mathcal{C}$: $C_{\\mathcal{C}} = \\$5{,}550$\n- Effectiveness of strategy $\\mathcal{C}$: $E_{\\mathcal{C}} = 7.778$ QALYs\n\nFirst, we calculate the incremental cost ($\\Delta C$):\n$$\n\\Delta C = C_{\\mathcal{N}} - C_{\\mathcal{C}} = \\$4{,}350 - \\$5{,}550 = -\\$1{,}200\n$$\nThe negative sign indicates that strategy $\\mathcal{N}$ is less costly than strategy $\\mathcal{C}$.\n\nNext, we calculate the incremental effectiveness ($\\Delta E$):\n$$\n\\Delta E = E_{\\mathcal{N}} - E_{\\mathcal{C}} = 7.982 \\text{ QALYs} - 7.778 \\text{ QALYs} = 0.204 \\text{ QALYs}\n$$\nThe positive sign indicates that strategy $\\mathcal{N}$ is more effective (provides more health benefit) than strategy $\\mathcal{C}$.\n\nNow, we can compute the ICER:\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta E} = \\frac{-\\$1{,}200}{0.204 \\text{ QALYs}} \\approx -5882.3529... \\frac{\\text{USD}}{\\text{QALY}}\n$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant digits are $5$, $8$, $8$, and $2$. The following digit is $3$, so we round down.\n$$\n\\text{ICER} \\approx -5882 \\frac{\\text{USD}}{\\text{QALY}}\n$$\n\nThe second part of the task is to classify and interpret this result.\nThe classification is based on the signs of the incremental cost and effectiveness. Here, $\\Delta C  0$ (negative) and $\\Delta E > 0$ (positive). This scenario places strategy $\\mathcal{N}$ in the southeast quadrant of the cost-effectiveness plane (where the x-axis represents $\\Delta E$ and the y-axis represents $\\Delta C$).\n\nThe interpretation of a negative ICER depends on the quadrant.\n1.  If $\\Delta C > 0$ and $\\Delta E  0$ (northwest quadrant), the new strategy is more expensive and less effective. It is \"dominated\" by the comparator, and the decision is to reject it.\n2.  If $\\Delta C  0$ and $\\Delta E > 0$ (southeast quadrant), the new strategy is less expensive and more effective. This is the current case. The new strategy is said to be \"dominant.\"\n\nIn this problem, strategy $\\mathcal{N}$ is dominant over strategy $\\mathcal{C}$. It achieves better health outcomes (more QALYs) at a lower cost. From a purely cost-effectiveness standpoint, the decision is straightforward: strategy $\\mathcal{N}$ should be adopted. The negative ICER of $-\\$5{,}882$ per QALY means that for every QALY gained by choosing strategy $\\mathcal{N}$ over strategy $\\mathcal{C}$, there is a cost saving of $\\$5{,}882$. The negative value signifies cost savings rather than an additional cost for the health gain.", "answer": "$$\\boxed{-5882}$$", "id": "4582264"}, {"introduction": "While some decisions are clear-cut, many public health interventions are more effective but also more expensive than the current standard of care. In these cases, the ICER alone does not tell us whether the extra cost is \"worth it.\" This practice introduces the concept of a willingness-to-pay (WTP) threshold, $\\lambda$, which represents the maximum amount a decision-maker is willing to spend for an additional unit of health gain. By using this threshold, we can calculate the Net Monetary Benefit (NMB) and Net Health Benefit (NHB) to arrive at a clear decision rule for adopting a new therapy [@problem_id:4970963].", "problem": "A health technology assessment body is evaluating a new chronic disease therapy (Drug A) versus standard care from a payer perspective over a lifetime horizon. The incremental analysis comparing Drug A to standard care yields an estimated incremental cost of $\\$15{,}000$ and an incremental effectiveness of $0.5$ Quality-Adjusted Life Years (QALYs). The decision-maker uses a willingness-to-pay threshold (WTP) of $\\$50{,}000$ per QALY for coverage decisions.\n\nUsing only the standard definitions of Incremental Cost-Effectiveness Ratio (ICER), Net Monetary Benefit (NMB), and Net Health Benefit (NHB) from cost-effectiveness analysis, compute:\n- the ICER,\n- the NMB at the given willingness-to-pay threshold,\n- the NHB at the given willingness-to-pay threshold,\nand determine whether Drug A should be adopted (assume adoption if the option is cost-effective at the WTP threshold).\n\nExpress the ICER in dollars per QALY, the NMB in dollars, and the NHB in QALYs. Round each computed quantity to $4$ significant figures.\n\nTo ensure a single numerical final answer, report your result as a four-entry row vector in the following order: $\\big[$ICER, NMB, NHB, decision indicator$\\big]$, where the decision indicator equals $1$ if Drug A is adopted and $0$ otherwise. Do not include units in the vector itself, but use the units specified above in your working.", "solution": "The problem is validated as sound and solvable. It is scientifically grounded in the principles of pharmacoeconomics, well-posed with all necessary information, and objective in its formulation.\n\nThe problem asks for the computation of three standard cost-effectiveness metrics and a subsequent adoption decision. The given values are:\n- Incremental cost, $\\Delta C = \\$15000$\n- Incremental effectiveness, $\\Delta E = 0.5$ Quality-Adjusted Life Years (QALYs)\n- Willingness-to-pay threshold, $\\lambda = \\$50000$ per QALY\n\nThe metrics to be computed are the Incremental Cost-Effectiveness Ratio (ICER), the Net Monetary Benefit (NMB), and the Net Health Benefit (NHB).\n\nFirst, we compute the ICER. The ICER represents the additional cost for each additional unit of health outcome (in this case, QALYs). The formula is:\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta E}\n$$\nSubstituting the given values:\n$$\n\\text{ICER} = \\frac{\\$15000}{0.5 \\text{ QALYs}} = \\$30000 \\text{ per QALY}\n$$\nThe problem requires rounding to $4$ significant figures. The exact value is $30000$. To express this with $4$ significant figures, we use scientific notation: $3.000 \\times 10^4$.\n\nSecond, we compute the NMB. The NMB translates the incremental health benefits into monetary terms using the WTP threshold and subtracts the incremental costs. A positive NMB indicates that the intervention is cost-effective. The formula is:\n$$\n\\text{NMB} = (\\lambda \\times \\Delta E) - \\Delta C\n$$\nSubstituting the given values:\n$$\n\\text{NMB} = (\\$50000/\\text{QALY} \\times 0.5 \\text{ QALYs}) - \\$15000 = \\$25000 - \\$15000 = \\$10000\n$$\nThe exact value is $10000$. To express this with $4$ significant figures, we use scientific notation: $1.000 \\times 10^4$.\n\nThird, we compute the NHB. The NHB translates the incremental costs into an equivalent \"health opportunity cost\" (in QALYs) and subtracts it from the incremental health benefits. A positive NHB indicates that the intervention is cost-effective. The formula is:\n$$\n\\text{NHB} = \\Delta E - \\frac{\\Delta C}{\\lambda}\n$$\nSubstituting the given values:\n$$\n\\text{NHB} = 0.5 \\text{ QALYs} - \\frac{\\$15000}{\\$50000/\\text{QALY}} = 0.5 \\text{ QALYs} - 0.3 \\text{ QALYs} = 0.2 \\text{ QALYs}\n$$\nThe exact value is $0.2$. To express this with $4$ significant figures, we write it as $0.2000$.\n\nFinally, we determine the adoption decision. An intervention is considered cost-effective if its ICER is less than or equal to the decision-maker's willingness-to-pay threshold ($\\lambda$).\n$$\n\\text{ICER} \\le \\lambda\n$$\n$$\n\\$30000/\\text{QALY} \\le \\$50000/\\text{QALY}\n$$\nThis condition is satisfied. The cost-effectiveness is independently confirmed by the positive NMB ($NMB = \\$10000 > \\$0$) and the positive NHB ($NHB = 0.2 \\text{ QALYs} > 0 \\text{ QALYs}$). Therefore, Drug A should be adopted. The decision indicator is $1$.\n\nThe final result is a row vector containing the four computed values in the specified order: $\\big[\\text{ICER, NMB, NHB, decision indicator}\\big]$, with the first three quantities rounded to $4$ significant figures.\n- ICER: $3.000 \\times 10^4$\n- NMB: $1.000 \\times 10^4$\n- NHB: $0.2000$\n- Decision indicator: $1$", "answer": "$$\n\\boxed{\\begin{pmatrix} 3.000 \\times 10^4  1.000 \\times 10^4  0.2000  1 \\end{pmatrix}}\n$$", "id": "4970963"}, {"introduction": "Real-world decision-making often requires comparing multiple mutually exclusive interventions, not just two. Simply calculating ICERs for all possible pairs can be misleading. This exercise introduces the critical process of identifying and eliminating inefficient strategies through the concepts of \"simple dominance\" and \"extended dominance.\" By systematically removing inferior options, you will learn how to construct the cost-effectiveness frontier, which represents the set of most efficient strategies from which a final decision should be made [@problem_id:4582253].", "problem": "A public health agency is evaluating three screening strategies for a chronic infectious disease over a lifetime horizon. All quantities below are already discounted to present value using a standard societal perspective. The agency considers Strategy $A$ (status quo), Strategy $B$ (moderate enhancement), and Strategy $C$ (intensive enhancement). For each strategy, the expected per-person cost in United States dollars (USD) and the expected per-person health benefit in Quality-Adjusted Life Years (QALYs) are as follows:\n- Strategy $A$: cost $275$ USD; effect $9.94$ QALYs.\n- Strategy $B$: cost $380$ USD; effect $9.96$ QALYs.\n- Strategy $C$: cost $510$ USD; effect $10.03$ QALYs.\n\nUsing foundational definitions from cost-effectiveness analysis in epidemiology, identify any simply dominated strategy by comparing costs and effects directly, and then assess extended dominance by ordering strategies by effect and comparing incremental trade-offs. Eliminate dominated options accordingly before computing any incremental cost-effectiveness ratios.\n\nAfter all simply dominated and extended dominated strategies are excluded, compute the Incremental Cost-Effectiveness Ratio (ICER) of the remaining efficient comparison on the frontier. Express your final answer in United States dollars (USD) per Quality-Adjusted Life Year (QALY) gained, and round to four significant figures.", "solution": "The problem will be validated by first extracting the given data and then assessing its scientific grounding, consistency, and structure.\n\n### Step 1: Extract Givens\nThe problem provides the following data for three public health screening strategies:\n- Strategy A (status quo): Cost $C_A = 275$ USD; Effect $E_A = 9.94$ QALYs.\n- Strategy B (moderate enhancement): Cost $C_B = 380$ USD; Effect $E_B = 9.96$ QALYs.\n- Strategy C (intensive enhancement): Cost $C_C = 510$ USD; Effect $E_C = 10.03$ QALYs.\n\nAll values are presented as expected per-person discounted present values.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem uses standard, well-defined concepts from health economics and epidemiology, including cost-effectiveness analysis, Quality-Adjusted Life Years (QALYs), simple dominance, extended dominance, and the Incremental Cost-Effectiveness Ratio (ICER). These are foundational principles for evaluating health interventions. The provided cost and effect values are plausible for a lifetime horizon analysis.\n2.  **Well-Posed**: The problem is clearly stated, providing all necessary data to perform the requested analysis. It asks for a specific sequence of analytical steps (identifying dominated strategies, then calculating a specific ICER), which leads to a unique, meaningful solution.\n3.  **Objective**: The problem is presented in objective, quantitative terms, free from subjective language or opinion.\n4.  **Completeness and Consistency**: The data is complete and internally consistent. There are no contradictions. Costs and effects both increase from Strategy A to B to C, which is a common scenario requiring ICER calculations.\n5.  **No Other Flaws**: The problem is not trivial, metaphorical, or unrealistic. It is a direct application of established analytical methods.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. It is a well-structured exercise in cost-effectiveness analysis. A complete solution will be provided.\n\n### Solution\nThe analysis begins by organizing the strategies according to their effectiveness, which is a prerequisite for correctly identifying dominated options and calculating incremental ratios. The strategies are ordered by increasing QALYs.\n\nLet $C_i$ be the cost and $E_i$ be the effect for strategy $i \\in \\{A, B, C\\}$. The provided data, already ordered by cost and effect, is:\n- Strategy A: $E_A = 9.94$ QALYs, $C_A = 275$ USD.\n- Strategy B: $E_B = 9.96$ QALYs, $C_B = 380$ USD.\n- Strategy C: $E_C = 10.03$ QALYs, $C_C = 510$ USD.\n\nThe order of increasing effectiveness is A, B, C.\n\n**Analysis of Simple Dominance**\nA strategy is simply dominated if another strategy is both more effective and less costly. We compare each pair:\n- Comparing B to A: $E_B > E_A$ ($9.96 > 9.94$) and $C_B > C_A$ ($380 > 275$). Neither strategy simply dominates the other.\n- Comparing C to B: $E_C > E_B$ ($10.03 > 9.96$) and $C_C > C_B$ ($510 > 380$). Neither strategy simply dominates the other.\n- Comparing C to A: $E_C > E_A$ ($10.03 > 9.94$) and $C_C > C_A$ ($510 > 275$). Neither strategy simply dominates the other.\nConclusion: There are no simply dominated strategies. All three strategies are potential candidates for the cost-effectiveness frontier.\n\n**Analysis of Extended Dominance**\nExtended dominance occurs when a strategy's incremental cost-effectiveness ratio (ICER) is greater than that of a more effective strategy. This means the intermediate strategy is inefficient compared to a combination of its less and more effective neighbors. We calculate the ICER for each sequential step on the ordered list of strategies.\n\nThe ICER is defined as the change in cost divided by the change in effect: $ICER = \\frac{\\Delta C}{\\Delta E}$.\n\n1.  Calculate the ICER for moving from Strategy A to Strategy B:\n    $$ICER_{A \\to B} = \\frac{C_B - C_A}{E_B - E_A} = \\frac{380 - 275}{9.96 - 9.94} = \\frac{105}{0.02} = 5250 \\text{ USD/QALY}$$\n\n2.  Calculate the ICER for moving from Strategy B to Strategy C:\n    $$ICER_{B \\to C} = \\frac{C_C - C_B}{E_C - E_B} = \\frac{510 - 380}{10.03 - 9.96} = \\frac{130}{0.07} \\approx 1857.14 \\text{ USD/QALY}$$\n\nNow, we compare the ICERs. For a set of non-dominated strategies, the ICERs should be strictly increasing.\nWe have $ICER_{A \\to B} = 5250$ and $ICER_{B \\to C} \\approx 1857.14$.\nSince $ICER_{A \\to B} > ICER_{B \\to C}$, the sequence of ICERs is not monotonically increasing. This indicates that Strategy B is subject to extended dominance. The cost per QALY gained by moving from A to B ($5250$) is higher than the cost per QALY gained by moving from B to C ($\\approx 1857.14$). This is inefficient. A decision-maker would be better off \"skipping\" strategy B and considering C directly against A.\n\nTherefore, Strategy B is eliminated from the set of efficient strategies.\n\n**Final ICER Calculation**\nAfter eliminating the extendedly dominated Strategy B, the remaining efficient comparison is between Strategy C and Strategy A. These two strategies now define the cost-effectiveness frontier. We compute the ICER for this final comparison.\n\n$$ICER_{A \\to C} = \\frac{C_C - C_A}{E_C - E_A} = \\frac{510 - 275}{10.03 - 9.94} = \\frac{235}{0.09}$$\n\n$$ICER_{A \\to C} = 2611.111... \\text{ USD/QALY}$$\n\nThe problem requires the answer to be rounded to four significant figures.\nThe number is $2611.111...$. The first four significant figures are $2$, $6$, $1$, and $1$. The fifth digit is $1$, so we round down.\nThe final ICER is $2611$ USD/QALY.", "answer": "$$\n\\boxed{2611}\n$$", "id": "4582253"}]}